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Summary 
Background 
The strongest risk factor for oesophageal adenocarcinoma (OAC) is reflux disease, and the rising 
incidence coincides with the eradication of Helicobacter pylori, both of which may alter the 
oesophageal microbiota. We aimed to profile the microbiota at different stages of Barrett’s 
carcinogenesis and investigate the Cytosponge™ as a minimally invasive tool for sampling the 
oesophageal microbiota.  
 
Methods 
16S rRNA gene amplicon sequencing was performed on 210 oesophageal samples from 86 
patients representing the Barrett’s progression sequence (normal squamous controls, non-
dysplastic and dysplastic Barrett’s oesophagus, and OAC), relevant negative controls and 
replicates on the Illumina MiSeq platform. Three different oesophageal sampling methods were 
compared for microbial DNA yield (qPCR), diversity and community composition: fresh frozen 
tissue, fresh frozen endoscopic brushings and the Cytosponge™ device. 
 
Findings 
There was decreased microbial diversity in OAC tissue compared to normal control patients as 
measured by the observed OTU richness, Chao estimated total richness and Shannon diversity 
index (all p<0·01). Lactobacillus fermentum was enriched in OAC (p=0·028), and lactic acid 
bacteria dominated the microenvironment in 7 (47%) of 15 OAC cases. Comparison of 
oesophageal sampling methods showed that the Cytosponge™ yielded more than ten-fold higher 
quantities of microbial DNA in comparison to endoscopic brushes (p<0·001) or biopsies 
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(p<0·0001) using qPCR. The Cytosponge™ samples contained the majority of taxa detected in 
biopsy and brush samples, but were enriched for genera from the oral cavity and stomach, 
including Fusobacterium, Megasphaera, Campylobacter, Capnocytophaga and Dialister. The 
Cytosponge™ detected decreased microbial diversity in patients with high grade dysplasia in 
comparison to controls as measured by the observed OTU richness, Chao estimated total richness 
and Shannon diversity index (all p<0·05). 
 
Interpretation  
Alterations in microbial communities occur in the lower oesophagus in Barrett’s carcinogenesis, 
which can be detected at the pre-invasive stage of high grade dysplasia using the novel 
Cytosponge™.  
 
Funding 
Cancer Research UK, National Institute for Health Research, Medical Research Council, and 
Wellcome Trust.  
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Introduction 
Oesophageal adenocarcinoma (OAC) is an aggressive malignancy with poor outcomes that 
generally develops from a pre-malignant columnar epithelium called Barrett’s oesophagus. The 
incidence of OAC has increased six-fold in the Western world during the past three decades.
1
 
Both Barrett’s and OAC are thought to develop in response to chronic acid reflux in the lower 
oesophagus, which precipitates inflammation and mucosal injury over time.
2
 Reflux disease has 
increased with the obesity epidemic and altered eating habits in the Western world, and central 
adiposity may also influence carcinogenesis through the release of adipokines.
3
 Epidemiologic 
evidence also suggests that the rising incidence of OAC coincides with the eradication of 
Helicobacter pylori, which may alter the composition of microbiota and promote bacterial 
overgrowth.
4
 Furthermore, reflux disease is treated with antacid medications such as proton 
pump inhibitors, which have profound effects on gastric acidity and may affect the gastro-
oesophageal microbiota.
5
  
 
There is growing evidence linking abnormal changes in the microbiota, or dysbiosis, with human 
cancer. One of the best described examples is colon carcinoma, in which gastrointestinal 
microbiota have been shown to promote carcinogenesis in the setting of colonic inflammation.
6-8
 
Recent evidence has also linked Fusobacterium nucleatum to colon carcinoma through an altered 
tumour immunoenvironment, but without associated colitis.
9,10
 The oesophagus has far fewer 
bacteria than the colon; nevertheless alterations in the microbiota may occur in reflux 
oesophagitis and Barrett’s oesophagus.11-13 However, the role of the microbiota in Barrett’s 
carcinogenesis is not clearly defined and there is currently no clinical reference standard for 
sampling the oesophageal microbiota. One of the challenges in studying the oesophageal 
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microbiota is that endoscopy is a relatively invasive test that provides only a focal sampling of 
the microbiota in biopsy samples and a slightly larger surface area with endoscopic brushings. 
Minimally invasive methods for sampling the oesophageal microbiota could be clinically useful 
for detection and risk stratification of patients with Barrett’s oesophagus. 
 
Here we propose the Cytosponge™ as a non-endoscopic cell-sampling device that can collect a 
representative sample of cells along the length of the oesophagus.
14,15
 The device consists of a 
spherical mesh compressed within a gelatine capsule and attached to a string. Once swallowed, 
the capsule dissolves and the Cytosponge™ expands in the patient’s stomach before being 
withdrawn on a string through the patient’s mouth. We have previously shown that this device is 
a safe, acceptable method for diagnosing Barrett’s oesophagus, with promising accuracy and 
cost-effectiveness characteristics.
14-16
 The goal of the current study was to provide a 
comprehensive description of the microbiota in the different pathogenic stages of OAC using 
16S rRNA gene amplicon sequencing and to test the feasibility of the Cytosponge™ to detect 
changes in the microbiota occurring in Barrett’s oesophagus and high grade dysplasia. 
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Methods 
Study design and participants 
Endoscopic biopsies, brushes, Cytosponge™ samples and throat swabs were collected from 
patients with a diagnosis of non-dysplastic Barrett’s oesophagus (n=24), high grade dysplasia 
(n=23) or control patients (n=20) with symptoms of reflux or dyspepsia enrolled in the Barrett’s 
Oesophagus Screening Trial (BEST2) at five UK hospitals. Matched endoscopic biopsies were 
taken from an area of Barrett’s oesophagus and proximal normal squamous oesophagus. 
Endoscopic brushings were taken from an area of normal squamous oesophagus only. In patients 
with a diagnosis of OAC, tissue samples from the tumour and matched normal squamous 
oesophagus (n=19) were collected from six UK hospitals participating in Oesophageal Cancer 
Clinical and Molecular Stratification (OCCAMS) for the International Cancer Genome 
Consortium (ICGC). The tissue samples collected in the OCCAMS/ICGC study included 
endoscopic biopsies, endoscopic mucosal resection specimens and surgical biopsies after 
oesophagectomy. Sampling from oesophagectomy specimens was performed with a sterile 
scalpel blade (cutting down to submucosa) within one hour of surgical resection. All samples 
were flash frozen in liquid nitrogen and stored at -80°C except the Cytosponge™ samples, which 
were preserved in BD SurePath™ liquid at 4°C. Table 1 displays patient demographics and the 
oesophageal samples sequenced. The number of patients recruited at each participating hospital 
centre and additional clinicopathologic data for the OAC patients is provided in the web 
appendix (pages 2–3). 
 
The patient inclusion criteria included age between 20 and 90 years, no current infection or 
antibiotics, no prior chemotherapy treatment, and no pathologic findings on endoscopy except 
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where Barrett’s oesophagus or OAC was documented. Acid-suppressant medication was taken 
regularly by 23 (100%) of 23 dysplastic cases, 22 (92%) of 24 Barrett’s cases, 12 (71%) of 17 
OAC cases (two not reported) and 15 (75%) of 20 controls. All patients were fasting overnight 
prior to endoscopy or surgery. As part of routine perioperative procedure, OAC patients who 
underwent oesophagectomy received prophylactic intravenous antibiotics at the time of surgery, 
up to six hours before the research samples were obtained. The very close timing of this 
perioperative antibiotic exposure should not critically affect microbial community composition 
profiles as 16S rRNA gene amplicon sequencing detects both live and dead bacterial cells cross-
sectionally (see Supplementary text).
17
 One patient with Barrett’s oesophagus and two patients 
with high grade dysplasia reported taking a course of antibiotics within the past month.  
 
Ethical approval was obtained from the National Research Ethics Services Cambridgeshire 
Research Ethics Committee on behalf of all hospital centres in the BEST2 trial (REC 
10/H0308/71, July 7, 2011) and the OCCAMS/ICGC trial (REC 07/H0305/52 and 10/H0305/51, 
February 7, 2010). Written informed consent was obtained from all subjects prior to the 
collection of samples and recording clinical information.  
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Table 1. Patient demographics and oesophageal samples  
 Patient diagnosis  
 
Control (n=20) Barrett's (n=24) Dysplasia (n=23) Cancer (n=19) p-value 
Median Age (Range) 57 (29–86) 67.5 (53–79) 65 (50–82) 70 (44–79) 0·001 
Male Sex (%) 7 (35) 16 (67) 19 (83) 15 (79) 0·006 
Caucasian Ethnicity (%) 19 (95) 24 (100) 23 (100) 16 (89), 1 NR 0·089 
Antacid usage (%) 15 (75) 22 (92) 23 (100) 12 (71), 2 NR 0·011 
Samples sequenced/passed QC     
 
Cytosponge™ 20/20 24 /24 23 /23  
 
Brush (squamous only) 19/19 19 /19   
 
Tissue 19/16 Barrett's: 24 /17  Cancer: 19 /15 
 
  Squamous: 24/15  Squamous: 19 /15  
NR=not recorded, QC=quality control as described in Methods. 
 
Procedures 
DNA extraction and 16S rRNA gene amplicon sequencing 
Cytosponge™ samples were vortexed and centrifuged to pellet cellular debris (215 g for 5 min), 
and the residual supernatant was used for microbial DNA extraction after further high speed 
centrigugation (14,000 g for 10 min). DNA was isolated from all oesophageal samples using the 
Precellys Soil DNA Kit (Peqlab Ltd.). The 16S rRNA gene was amplified using primers for the 
V1-V2 region: 27F 5’AATGATACGGCGACCACCGAGATCTACAC TATGGTAATT CC 
AGMGTTYGATYMTGGCTCAG and 338R 5’CAAGCAGAAGACGGCATACGAGAT 
NNNNNNNNNNNN AGTCAGTCAG AA GCTGCCTCCCGTAGGAGT, where Illumina 
adapter sequences are at the 5’ end, and the N string is a unique barcode. The majority of 
samples had two barcoded replicates to ensure reproducibility (labelled “A” or “B” in the web 
appendix, page 4). The reaction conditions were 98°C for two minutes, 25 cycles of 98°C for 30 
s, 50°C for 30 s, 72°C for 90 s, and extension at 72°C for five minutes. Negative controls were 
kit reagents or nuclease free water, and underwent 45 amplification cycles. All samples were 
amplified in duplicate and pooled to minimize PCR bias and maximize yield. The PCR products 
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were concentrated using ethanol precipitation and quantified using a Qubit 2.0 Fluorometer prior 
to sequencing on the MiSeq Illumina platform using 2 x 250 bp read length. 16S rRNA gene 
amplicon sequencing data has been deposited in the European Nucleotide Archive under 
accession number ERP005191: http://www.ebi.ac.uk/ena/data/view/ERP005191.  
 
Analysis of 16S rRNA gene amplicon sequence data  
The 16S rRNA gene amplicon sequence analysis was performed using mothur.
18
 The Miseq 
standard operating procedure
19
 was followed with the exception of chimera checking, which was 
performed with chimera.perseus, and unique sequences were removed using the split.abund and 
remove.seqs commands prior to building the distance matrix. Contaminant OTUs were defined 
as having greater proportional abundance in negative controls, alongside previous evidence that 
these OTUs were derived from genera that are common contaminants,
20
, and these reads were 
removed using remove.seqs (3434 OTUs defined as contaminants from 5757 total OTUs). 
Comparisons between replicate samples (using Metastats
21
 as implemented in mothur) revealed 
no significant differences so replicates were pooled using the Linux sed command to maximize 
the number of reads per sample, and samples with fewer than 550 reads and/or Good’s coverage 
less than 95% were removed using remove.groups. The Good’s coverage estimator22 is used to 
assess what proportion of the total OTUs present within a given sample are detected in the 
sequencing results, and thus gives an indication of how thorough the sampling has been at the 
chosen sequencing depth. For measures of diversity that are sensitive to the sequencing depth, 
random sub-sampling was performed at the lowest number of reads per sample using the 
sub.sample command in mothur. Data were sub-sampled at 631 reads for the analysis of tissue 
samples (median Good’s coverage 96.36%, range 92.08%–99.37%), 656 reads for matched 
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tumour-normal pairs (median Good’s coverage 97.41%, range 95.27%–98.78%), 631 reads for 
the comparison of different sampling methods (median Good’s coverage 96.51%, range 91.13%–
99.84%), and 19303 reads for the analysis of Cytosponge™ samples (median Good’s coverage 
99.83%, range 99.70%–99.95%). When determining the shared genera between Cytosponge™ 
samples, biopsies and brushes a cut-off of 0.0001% proportional abundance was used to focus on 
the more abundant OTUs that are less likely to be susceptible to errors introduced by 
subsampling (below 0.0001% there were less than 27 reads supporting each OTU across all the 
samples). A second cut-off value of 0.1% was chosen arbitrarily to show the similarity between 
sample types and is a common cut-off used in the literature. Sequence identity was confirmed at 
the species level where possible by carrying out NCBI BLAST analysis on representative 
sequences using MegaBLAST.
23
 
 
Quantitative PCR for overall bacterial abundance 
Quantitative PCR for the 16S rRNA gene was performed using SYBR Green I Master Mix 
(Roche) on the LC480 LightCycler 480 II (Roche), in triplicate. The reaction conditions were 
95°C for five minutes, 40 cycles of 95°C for 15 s, 60°C for 30 s and 72°C for 90 s, and a melt 
curve. The primer sequences were 331F 5’TCCTACGGGAGGCAGCAGT and 797R 
5’GGACTACCAGGGTATCTAATCCTGTT.24 
 
 Statistical Analysis 
The nonparametric Kruskal-Wallis test and Dunns multiple comparisons post-test were used for 
comparisons between diagnostic groups in Graphpad Prism version 6. Within Graphpad, the 
Wilcoxon signed rank test was used for analyses involving matched tumour-normal pairs and the 
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Friedman test and Dunns post-test were used for analyses of matched samples from endoscopic 
biopsies, brushes and the Cytosponge™. Linear discriminant analysis effect size (LEfSe)25 was 
used within mothur to compare differences in proportional abundance of microbial taxa. All 
sequencing reads were included for the composition analysis using LEfSe. LEfSe ranks OTUs in 
order that it considers these taxa to be most likely to explain differences between microbial 
communities using linear discriminant analysis (LDA) to estimate effect size. A full explanation 
of the statistical approaches employed in LEfSe can be found in the original paper by Segata et 
al.
25
 Within mothur, the Bray-Curtis calculator was used to describe the dissimilarity between 
communities by taking into account both the overlap in OTUs that are present between samples 
and the proportional abundance of those OTUs in each sample. Using dissimilarity information 
calculated with the Bray-Curtis calculator, the parsimony test and the analysis of molecular 
variance (AMOVA) test were used to indicate significantly different clustering between 
microbiota profiles from the different diagnostic groups. IBM SPSS Statistics Version 24 was 
used to analyse patient data (ANOVA for mean age and Fisher’s Exact test for sex, ethnicity and 
antacid usage). A significant p-value was defined as less than 0·05. 
 
Role of the funding source 
The funding sources had no role in the study design, analysis, interpretation of data or writing of 
the report. 
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Results 
To investigate whether the development of OAC was associated with dysbiosis, we performed 
16S rRNA gene amplicon sequencing on tissue samples from patients with OAC (n=19), 
Barrett’s oesophagus (n=24) and normal control patients (n=19, table 1). Patients with OAC and 
Barrett’s were older (p=0·001) and were predominantly male (p=0·025) in comparison to the 
controls, which is consistent with the known epidemiology of this disease.
26
 The majority of 
samples had two barcoded replicates to ensure reproducibility (web appendix, page 4), and 
negative controls from every DNA extraction step underwent additional PCR cycles to identify 
contaminant organisms. After filtering the sequencing data and removing contaminant 
sequences, the average number of reads for tissue samples was 6649 (median 3064) and the 
proportion of reads that were sub-sampled for diversity analyses was 9.5% (for 631 reads cut-
off) and 9.9% (for 656 reads cut-off). Fourteen tissue samples did not meet quality criteria and 
were excluded from the analysis, leaving 16 controls, 17 Barrett’s and 15 OAC samples. Five 
phyla accounted for the majority of sequencing reads in the dataset: Firmicutes (59·9%), 
Bacteroidetes (15·1%), Proteobacteria (12·8%), Actinobacteria (5·8%) and Fusobacteria 
(5·4%). 1060 operational taxonomic units (OTUs) were identified and classified as belonging to 
345 different genera. 
 
We used linear discriminant analysis effect size (LEfSe), a metagenomic biomarker discovery 
method, to identify microbial taxa that differed significantly between controls, Barrett’s and 
OAC samples. At the phylum level, the Barrett’s samples contained a higher proportional 
abundance of Proteobacteria (mean 18·6%, median 14·8%, p=0·017) compared to controls 
(mean 8·5%, median 8·2%) and OAC samples (mean 7·6%, median 3·9%). The control samples 
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were enriched for several taxa at the family level, including the Gram-negative, anaerobic 
Veillonellaceae (p=0·012, overall proportional abundance 5·3%) and microaerophilic 
Campylobacteraceae (p=0·00038, overall proportional abundance 0·2%), the Gram-positive, 
anaerobic Lachnospiraceae (p=0·012, overall proportional abundance 1%) and 
Erysipelotrichaceae (p=0·0021, overall proportional abundance 0·4%), and the Gram-positive, 
facultative anaerobic Carnobacteriaceae (p=0·038, overall proportional abundance 1·6%) and 
Actinomycetaceae (p=0·0019, overall proportional abundance 0·8%, figure 1A). Significant 
genera within these families included Veillonella (p=0·002, overall proportional abundance 
3.8%), Megasphaera (p=0·0027, overall proportional abundance 0.3%), Granulicatella 
(p=0·037, overall proportional abundance 1.6%), Actinomyces (p=0·0022, overall proportional 
abundance 0.8%), Solobacterium (p=0·012, overall proportional abundance 0.3%) and 
Campylobacter (p=0·0004, overall proportional abundance 0.2%, figure 1B). In OAC samples, 
the Gram-positive, anaerobic Coriobacteriaceae was enriched at the family level (p=0·01, 
overall proportional abundance 1·9%), but there were no significant genera identified within this 
family. At the species level, the Gram-positive, facultative anaerobic Lactobacillus fermentum 
was enriched in OAC with mean proportional abundance of 0·6% (median 0·009%) compared to 
0·01% (median 0%) in Barrett’s and 0·004% (median 0%) in controls (p=0·028). Sequence 
identity was confirmed where possible using NCBI BLAST. One Barrett’s sample contained a 
high proportional abundance of Helicobacter pylori sequences (>99%). 
 
Typically, OAC samples clustered away from controls in a Bray-Curtis cluster dendrogram 
(p=0·002, parsimony test), emphasizing the difference in community structure (figure 2A). The 
Bray-Curtis algorithm describes the dissimilarity between communities by taking into account 
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both the overlap in OTUs that are present and the proportional abundance of those OTUs. 
Samples that have fewer overlapping OTUs and OTUs with less similar proportional abundances 
will cluster separately, and this differential clustering was further demonstrated by principal 
coordinate analysis (p=0·001, AMOVA test, web appendix, page 1). The microbial communities 
of 7/15 OAC samples were dominated by the Gram-positive order Lactobacillales. Of the seven 
patients with a high proportion of acid-tolerant Lactobacillales, six were taking antacid 
medication. Five OAC samples contained high proportional abundance of Streptococcus (69% to 
98%) and two samples contained high proportional abundance of Lactobacillus (87% and 92%). 
NCBI BLAST showed that the representative species were Streptococcus pneumoniae/mitis, 
Streptococcus salivarius/vestibularis, Streptococcus parasanguinis, Lactobacillus gasseri, and 
Lactobacillus helveticus/suntoryeus/gallinarum. Although relatively abundant in the acidic 
stomach environment, such a high proportional abundance of Lactobacillus was an unexpected 
finding in the oesophagus. When we examined matched normal and tumour tissue for the two 
patients with high Lactobacillus we found that this genus dominated the lower oesophagus 
regardless of disease state, (figure 2B). Gram-positive rods were visualized in areas of ulceration 
in tumour PS003 with a high proportional abundance of Lactobacillus (figure 2C).  
 
Alpha diversity refers to the species diversity within a given environment and includes the 
number of species (“richness”) and the proportion of those species (“evenness”) within the 
microbial community. Three indices of alpha diversity, observed OTU richness (p=0·0012, 
figure 3A), the Chao estimate of total OTU richness (p=0·0004, figure 3B), and the Shannon 
diversity index (p=0·0075, figure 3C), showed that diversity was lower in OAC samples 
compared to controls. In comparison to Barrett’s samples, the OAC samples showed a decrease 
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in observed OTU richness and the Chao estimate, but not the Shannon diversity index. Thirteen 
OAC patients had matched normal squamous tissue sampled proximal to the tumour, and in 
these patients there was no difference in OTU richness between the normal and tumour tissue 
(p=0·9065, figure 3D). Similarly, there was no difference for the Chao estimate (p>0·999) or the 
Shannon index (p=0·6355). Furthermore, there was no difference in overall bacterial abundance 
between matched normal squamous and tumour tissue (p=0·782, figure 3E). These results 
suggested that the decreased microbial diversity was pervasive throughout the lower oesophagus 
in OAC and independent of the absolute quantity of oesophageal bacteria.  
 
We performed additional analyses to ensure that the differences observed were not due to sex, 
age or acid suppression. We repeated the diversity analysis with male patients only (excluded 10 
controls, 4 Barrett’s and 3 cancer cases), and the results were consistent, with decreases in 
diversity in cancer samples compared to controls for the observed OTU richness (p=0·0029), the 
Chao estimate of total OTU richness (p=0·0017), and the Shannon diversity index (p=0·0070). 
We repeated the diversity analysis with patients 60 years and older (excluded 9 controls, 2 
Barrett’s and 2 cancer samples), and the results showed a similar trend, which was significant for 
the observed OTU richness (p=0·0448), the Chao estimate of total OTU richness (p=0·0288), but 
not the Shannon diversity index (p=0·0892). We also performed a subgroup analysis for age 
within each diagnostic subgroup (using median age as a cut-off within each group) and there 
were no significant differences in diversity for younger vs. older patients within any of the 
subgroups. When we excluded patients who were not taking acid suppression (4 control patients, 
2 Barrett’s patients, 4 cancer patients) or unknown (1 cancer patient) the results were similar, 
with decreased diversity in OAC samples compared to controls, as evidenced by the observed 
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OTU richness (p=0·0065), the Chao estimate of total OTU richness (p=0·0033), and the Shannon 
diversity index (p=0·0202). 
 
Given that the decrease in microbial diversity in OAC appeared widespread throughout the 
oesophagus, we questioned whether the Cytosponge™ could be a useful tool to sample the 
microbiota along the entire length of the oesophagus and upper GI tract. Fifteen patients with 
Barrett’s oesophagus and 16 controls had Cytosponge™ samples that underwent 16S rRNA gene 
amplicon sequencing with matched endoscopic biopsies and brushes taken from an area of 
normal squamous oesophagus. A subset of these patients also had swabs of their posterior 
pharynx to analyse the similarities and differences between the oesophageal and oral microbiota 
(n=13). Overall 1455 OTUs were identified and mapped to 381 genera. Using a cut-off of 
0·0001% overall proportional abundance (138 genera classified), 84·1% of genera were shared 
between Cytosponge™ samples, biopsies and brushes, and 83·6% were shared between 
Cytosponge™ samples and throat swabs. A stricter cut-off of 0·1% overall proportional 
abundance (41 genera classified) showed supporting reads for 100% of genera in all sample 
types, indicating overlap in community membership between the oral cavity, oesophagus and 
gastric cardia.  
 
Although the majority of microbial taxa overlapped between sample types, the proportional 
abundances differed. At the phylum level, the Cytosponge™ samples contained a higher 
proportional abundance of Tenericutes in comparison to the other sample types using LEfSe 
(p=4·7x10
-5
, overall proportional abundance 0.2%). At the genus level, the Cytosponge™ 
samples contained greater proportional abundances of Fusobacterium (p<0·0001, overall 
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proportional abundance 2%), Megasphaera (p<0·0001, overall proportional abundance 1.8%), 
Campylobacter (p<0·0001, overall proportional abundance 1.7%), Capnocytophaga (p=0·00058, 
overall proportional abundance 0.7%) and Dialister (p<0·0001, overall proportional abundance 
0.2%). In keeping with these findings, principal coordinate analysis using the Bray-Curtis 
algorithm demonstrated that the Cytosponge™ samples clustered away from the throat swabs, 
endoscopic biopsies and brushes (p<0·001, AMOVA test, figure 4A). The throat swabs clustered 
distinctly from all the other sample types as well (p<0·001). There was no difference in 
clustering between biopsies and brushes on the PCoA plot (p=0·459).  
 
As expected due to increased sampling surface area, quantitative PCR of overall bacterial 
abundance showed the quantity of microbial DNA isolated from Cytosponge™ samples was 
greater than matched biopsies and brushes (n=20 patients, p<0·0001, figure 4B). After sub-
sampling to normalize for sequencing depth there was a decrease in observed OTU richness 
(p=0·0104, figure 4C) and the Chao estimate of total OTU richness (p=0·0156, figure 4D) in 
endoscopic brush samples, but no difference for the Shannon index (p=0·5968, figure 4E). To 
translate our findings to the setting of early detection, we tested the utility of the Cytosponge™ 
to detect changes in microbial diversity in patients with high grade dysplasia (n=23). The 
average number of reads for Cytosponge™ samples was 40753 (median 40821), and the 
proportion of reads that were sub-sampled was 47% (for 19303 reads cut-off). The observed 
OTU richness was decreased in high grade dysplasia compared to controls (p=0·0147, figure 
5D), as was the Chao estimate of total OTU richness (p=0·023, figure 5E) and the Shannon index 
(p=0·0085, figure 5F). There was a trend towards decreased diversity in Barrett’s oesophagus, 
which was only significant for the Shannon index. In general, the Cytosponge™ samples showed 
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more homogenous results for microbiota composition between diagnostic groups at the phylum 
and family levels, suggesting that the fraction of microbiota sampled from the area of Barrett’s 
was diluted by the copious bacteria sampled from the rest of the oesophagus, oral cavity and 
stomach. Despite this, three genera were identified that distinguished controls from the other 
sample types using LEfSe: Dialister (p=0·027, overall proportional abundance 0.3%), 
Schlegelella (p=0·016, overall proportional abundance 0.1%) and unclassified Prevotellaceae 
(p=0·047, overall proportional abundance 1.3%). 
 
Discussion 
Our sequencing data revealed decreased microbial diversity and altered community composition 
in OAC. Interestingly, OAC patients appeared to have this reduced diversity regardless of 
whether cancerous or normal oesophageal tissue was sampled. The genera that were decreased in 
proportional abundance in OAC included Gram-negative (Veillonella, Megasphaera and 
Campylobacter) and Gram-positive taxa (Granulicatella, Atopobium, Actinomyces and 
Solobacterium). There was significantly increased proportional abundance for Lactobacillus 
fermentum in OAC compared to control patients and Barrett’s oesophagus, and there was a high 
proportional abundance of acid-tolerant Lactobacillales (Lactobacillus and Streptococcus) in a 
subset (7/15) of OAC samples. To translate our findings to the setting of early detection, we 
investigated the utility of the Cytosponge™ device for sampling the oesophageal microbiota in 
Barrett’s oesophagus and high grade dysplasia. The Cytosponge™ had high microbial DNA 
yield and detected significantly decreased diversity in high grade dysplasia compared to control 
patients.  
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Lactobacillales, or lactic acid bacteria, are so named for their ability to produce lactate from the 
fermentation of carbohydrates and survive under harsh acidic conditions.
27
 Their resilience to 
low pH may enable Lactobacillus and Streptococcus to thrive in the tumour niche in a subset of 
OAC patients, and production of lactic acid by these bacteria could further acidify the 
microenvironment. Lactic acid fermentation can also produce noxious byproducts such as 
hydrogen peroxide that directly inhibit the growth of competitor bacteria and enable 
Lactobacillales to dominate the lower oesophagus. Given the altered microbial composition in 
OAC samples, it would be interesting to correlate microbiota data with expression and activity of 
Toll-like receptors, particularly TLR2, given the increased proportional abundance of Gram-
positive genera in a subset of cancer samples. Other authors have investigated TLR expression in 
Barrett’s carcinogenesis and found overexpression of TLRs 1, 2, 4, 6 and 9 in human OAC 
samples
28-31
 and TLRs 1-3, 6, 7 and 9 in a rat reflux model.
32
 
 
While the microbial community structure differed significantly in OAC in our study, there was 
only a modest reduction in diversity in Barrett’s oesophagus and no genera were identified that 
discriminated between controls and Barrett’s, or Barrett’s and OAC. It is possible that very low 
abundance genera may be difficult to detect in oesophageal biopsies given the low microbial 
DNA yield, and notably some pathogens have been shown to cause overt disease while only 
accounting for a low proportional abundance of the total microbiota, such as Clostridium 
difficile,33,34 Citrobacter rodentium and Fusobacterium spp.
35
 Similarly, Amir et al. were unable 
to identify any taxa that differentiated between controls (n=15) and Barrett’s (n=6) or 
oesophagitis (n=13) using LEfSe.
5
 In contrast, Yang et al. reported that Gram-negative bacteria 
were significantly enriched in Barrett’s (n=10) and reflux oesophagitis (n=12) compared to 
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controls (n=12).
11
 The main limiting factor of these microbiota studies is the relatively small 
sample size and inter-individual variation in microbiota composition. Another limitation is that 
while LEfSe is useful for biological interpretation of metagenomic data, it does not correct for 
multiple comparisons so there is a risk of false discovery (p-value, α=0·05). The inclusion of 
appropriate negative controls and replicate samples is also paramount for low microbial biomass 
samples to facilitate removal of contaminant OTUs that may also lead to false discovery,
20
 and 
this was a major strength of our study. We also imposed strict quality control criteria, resulting in 
the exclusion of 14 tissue samples with low sequencing read numbers and Good’s coverage 
estimates. The difficulty in obtaining good quality sequencing data from oesophageal samples 
highlights the potential utility of the Cytosponge™ device, which samples a larger surface area.  
 
Our results suggest that it is feasible to sample the oesophageal microbiota using the 
Cytosponge™, and the device detected the majority of genera present in endoscopic biopsies and 
brushes. The high microbial DNA yield collected by the Cytosponge™ reflects sampling the 
entire length of the oesophagus as well as the proximal stomach and oral cavity as it is 
withdrawn. The throat swabs showed similarities in community membership between the oral 
cavity and oesophagus, but the proportional abundances differed as reflected by distinct 
clustering in principal coordinate analysis. Despite dilution from sampling the upper GI tract, it 
was still possible for the Cytosponge™ to detect a decrease in diversity and community 
composition between normal squamous controls and high grade dysplasia. Similar to the 
Cytosponge™, Fillon et al. described a minimally invasive oesophageal string test to sample the 
microbiota in a paediatric population.
36
 The oesophageal string test detected comparable 
microbial composition to matched oesophageal biopsies but required the patients to remain in 
 21 
hospital overnight with the string secured to their cheek. Alternatively, the Cytosponge™ is a 
convenient test that can be administered in a General Practitioner’s office with the supervision of 
a trained nurse, and takes only 5-7 minutes to complete.
14,37
 The Cytosponge™ can also provide 
histologic data for inflammatory pathologies such as candidal oesophagitis, herpes oesophagitis 
and eosinophilic oesophagitis.
38
 Our initial results using the Cytosponge™ are promising, and 
future test development should focus on longitudinal sampling of the microbiota to monitor for 
changes in microbial diversity over time in a larger cohort of patients. Further research should 
also examine the role of diet, dysphagia and other external influences on the oesophageal 
microbiota. 
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Research in context 
Evidence before this study 
Epidemiologic evidence suggests that the rising incidence of oesophageal adenocarcinoma 
(OAC) coincides with the obesity epidemic, gastrooesophageal reflux disease and eradication of 
Helicobacter pylori using antibiotics and acid suppression therapy – all risk factors that are 
capable of altering the gastrooesophageal microbiota. Three studies with small numbers of 
patients have shown modest alterations in the microbiota in Barrett’s oesophagus and 
oesophagitis using 16S rRNA gene amplicon sequencing. However, studies using culture-
independent methods to profile the oesophageal microbiota in OAC or high grade dysplasia are 
currently lacking. One explanation for the scarcity of oesophageal microbiota studies is the 
challenge of endoscopic sampling and low microbial DNA yield. Based on prior publications, we 
hypothesized that the novel Cytosponge™ could be an effective tool to sample the microbiota 
along the entire length of the oesophagus. 
Added value of this study 
This study provides a comprehensive characterisation of the microbiota at different stages of the 
Barrett’s progression sequence using 16S rRNA gene amplicon sequencing, and compares OAC 
and Barrett’s cases to normal control patients. We found decreased microbial diversity in OAC 
tissue compared to controls with enrichment of acid-tolerant bacteria such as Lactobacillus 
fermentum. The microbial diversity was reduced in the lower oesophagus regardless of whether 
cancerous or normal oesophageal tissue was sampled within the same patients. We further 
translated our findings to the setting of early detection using the Cytosponge™ to sample the 
microbiota in Barrett’s oesophagus and high grade dysplasia. We showed that the Cytosponge™ 
collected high microbial DNA yield and detected decreased diversity in the pre-invasive stage of 
high grade dysplasia.  
Implications of all the available evidence 
Alterations in microbial communities occur in the lower oesophagus in Barrett’s carcinogenesis, 
which are possible to detect using the minimally invasive Cytosponge™. Our findings are 
potentially applicable to early disease detection, and future test development should focus on 
longitudinal sampling of the microbiota to monitor for changes in microbial diversity in a larger 
cohort of patients. 
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Figure 1. Proportional abundance of microbial taxa differs in Barrett’s carcinogenesis. (A) Mean proportional 
abundance of the 8 most prevalent phyla and 25 most prevalent families in tissue samples for normal control patients 
(n=16), Barrett’s (n=17) and OAC (n=15), significant differences calculated using LEfSe (* p<0·05, ** p<0·01, *** 
p<0·001). Error bars are standard error of the mean. (B) Mean proportional abundance of representative genera from 
significantly enriched families identified in A. Only genera with overall proportional abundances greater than 0·1% 
are included.  
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Figure 2. Microbial community composition is altered in OAC. (A) The OAC and control patient groups largely 
cluster away from each other in this Bray-Curtis cluster dendrogram (p=0·002, parsimony test), but there is no 
significant difference in clustering for Barrett’s oesophagus. Microbial composition is illustrated at the family level 
for each tissue sample. Data were sub-sampled at 631 reads per sample. (B) Lactobacillus is the dominant taxon in 
two tumour samples (PS003 and RS013) and matched normal squamous tissue. (C) Tumour sample PS003 stained 
with haematoxylin and eosin, scanned at 20X magnification, imaged at 5% digital zoom. Inserts show Gram stain 
with Gram-positive rods, imaged at 50% or 100% digital zoom. 
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Figure 3. Alpha diversity is decreased throughout the lower oesophagus in OAC. (A) Observed richness of 
bacterial operational taxonomic units (OTUs), (B) the Chao estimate of total OTU richness, and (C) the Shannon 
diversity index are shown for tissue samples from normal controls (n=16), Barrett’s (n=17) and OAC (n=15) 
patients. Statistical significance calculated using Kruskal-Wallis test and Dunns multiple comparisons post-test (* 
p<0·05, ** p<0·01, *** p<0·001). Data were sub-sampled at 631 reads per sample. (D) Observed richness of 
bacterial OTUs for paired normal and tumour tissue samples 13 patients (26 samples), Wilcoxon signed rank test. 
Data were sub-sampled at 656 reads per sample. (E) Overall bacterial abundance using 16S rRNA gene qPCR in 
matched tumour and normal squamous tissue from 16 patients (32 samples), Wilcoxon signed rank test. Error bars 
represent standard deviation. 
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Figure 4. The Cytosponge™ has high microbial DNA yield and detects decreased alpha diversity in high 
grade dysplasia (A) Principal coordinate analysis using the Bray-Curtis algorithm for matched endoscopic biopsies, 
brushes and Cytosponge™ samples (n=31 patients) and 13 throat swabs from a subset of these patients. The first 
axis (PC1) accounts for 19·6% of the sample variance and the second axis (PC2) accounts for 6·3% of the variance. 
Data were sub-sampled at 631 reads per sample. (B) Overall bacterial abundance using 16S rRNA gene-based qPCR 
in matched endoscopic biopsies, brushes and Cytosponge™ samples (n=20 patients), Friedman test and Dunns 
multiple comparisons post-test (* p<0·05, ** p<0·01, *** p<0·001, **** p<0.0001). (C) The observed diversity of 
bacterial OTUs, (D) the Chao estimate of total OTU richness, and (E) the Shannon diversity index for matched 
endoscopic biopsies, brushes and Cytosponge™ samples (n=31 patients), Friedman test and Dunns multiple 
comparisons post-test. Data were sub-sampled at 631 reads per sample. (F) Observed richness of bacterial 
operational taxonomic units (OTUs), (G) the Chao estimate of total OTU richness, and (H) the Shannon diversity 
index for Cytosponge™ samples taken from normal squamous controls (n=20), Barrett’s (n=24) and high grade 
dysplasia (n=23) patients. Statistical significance calculated using Kruskal-Wallis test and Dunns multiple 
comparisons post-test. Data were sub-sampled at 19303 reads per sample. Error bars represent standard deviation.  
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